Aine Cryts
Aine Cryts is a freelancer based in Boston. She is a frequent contributor to Managed Healthcare Executive on topics such as diabetes, oncology, hospital admissions and readmissions, senior patients, and health policy.
Successful payer-provider collaborations: 4 characteristics
Successful payer-provider collaborations: 4 characteristics
While value-based reimbursement presents opportunities for payers and providers, succeeding in such a reimbursement model can be challenging. Here are four things to strive for that could increase the likelihood of success in a value-based reimbursement model.
Measuring payer, provider progress in the move to value
In the move to value-based care, there have been surprises and disruptions for payers and providers alike. In this Q&A, an expert shares where we are now.
Seven risk-sharing mistakes to avoid in healthcare
Seven risk-sharing mistakes to avoid in healthcare
Considering entering into a risk-sharing agreement with another payer or provider? Avoid these top mistakes.
Is value-based pay leading to more MD face time?
In the fee-for-service world, physicians need to squeeze in more visits into less time. Here’s how value-based reimbursement is changing the model.
ICD-10 impact on reimbursement, payers, and providers
How did the ICD-10 transition impact health systems and health plans? Here, those in the field, weigh in.
Five tech trends that will change the healthcare industry
Five tech trends that will change the healthcare industry
New technology is changing how payers, providers, and patients interact. Stay ahead of the curve by monitoring these technology changes.
Six new skills needed by healthcare executives
As the healthcare industry changes, health plan executives must master new skills.
Experts predict reimbursement changes for 2016
What reimbursement changes can healthcare executives expect in 2016? Three experts weigh in.
The changing face of healthcare leadership
The changing face of healthcare leadership
The changing healthcare industry is leading organizations to prioritize new skill sets during recruitment efforts.
Reimbursement hurdles associated with biosimilars
Optimism exists for biosimilars in the United States, but questions regarding FDA approval and reimbursement remain.

Poll

View Results